Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRI BioGRI -1.16%33 5-Year Yield-on-Cost % is 0.00 as of Aug. 19, 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 149 Biotechnology companies, GRI Bio ranks worse than 671140.27% on this metric.
GRI Bio's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for GRI Bio's 5-Year Yield-on-Cost % or its related term are showing as below:
GRI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GRI Bio (NAS:GRI) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
GRI Bio 5-Year Yield-on-Cost % Related Terms
GRI vs ISCO, VRAX, SLXN: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, GRI Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRI Bio 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GRI Bio's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where GRI Bio's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of GRI Bio is calculated as
GRI Bio (GRI) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 19, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GRI Bio and its competitors. According to the industry distribution chart, GRI Bio ranks #999999 out of 149 companies in the Biotechnology industry.
Is GRI Bio's 5-Year Yield-on-Cost % too high?
GRI Bio's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, GRI Bio ranks #999999 out of 149 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's 5-Year Yield-on-Cost % compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #999999 out of 149 companies for 5-Year Yield-on-Cost %. This places GRI Bio in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 149 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on GRI Bio and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRI Bio's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For GRI Bio (GRI), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score
Get the complete analysis for GRI
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRI has been successfully added to your 
